The Gelfand Clinical Research Lab designs and conducts clinic-based and population-based observational studies and interventional and translational clinical trials in common and rare skin diseases. Dr. Gelfand and his team focus on pharmacoepidemiology, patient-centered outcomes and effectiveness research, psychometrics and instrument/diagnostic test development, and human translational studies aimed at the development of novel treatment approaches and further understanding of disease pathogenesis. A major goal of the Gelfand Clinical Research Program is to improve psoriasis patient outcomes in the skin and joints, while lowering the risk of diabetes, cardiovascular disease and mortality. A full list of our current research projects can be found in the Research tab.
Welcome to our newest members of the team!
Read more about them on our Team page.
Most recent publications:
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial
The JID: A Scientific Home for Innovative, Rigorously Conducted, Clinical, and Epidemiologic Research in Dermatology from Around the World
Opportunities in the Gelfand Lab:
Join Us on the Research Bus to Success!